Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

This study has been completed.

First Received: May 2, 2007 Last Updated: August 21, 2007 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00468988

Purpose

Compare the effect of Xalatan with benzalkonium chloride on the ocular surface to those effects observed with Travatan Z without benzalkonium chloride after a single dose

Condition	Intervention	Phase
Glaucoma	Drug: Travatan® Z Drug: Xalatan®	Phase IV

Genetics Home Reference related topics: early-onset glaucoma

MedlinePlus related topics: Glaucoma

Drug Information available for: Chlorides Latanoprost Travoprost Benzalkonium chloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Single Blind, Active Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Short Term Comparative Study of Xalatan With Benzalkonium Chloride vs. Travatan Z Without Benzalkonium Chloride in Healthy Volunteers

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Tear Break Up Time [ Time Frame: Day ]

Secondary Outcome Measures:

Safety [ Time Frame: Onset ]

Estimated Enrollment:	30
Study Start Date:	May 2007

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

Adults with primary open-angle glaucoma, ocular hypertension or pigment dispersion glaucoma

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00468988

Locations

United States, Florida
Orlando
Orlando, Florida, United States, 32801

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Mark Jasek, PhD

Alcon Research

More Information

No publications provided

Study ID Numbers:	SMA-06-21
Study First Received:	May 2, 2007
Last Updated:	August 21, 2007
ClinicalTrials.gov Identifier:	NCT00468988 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Anti-Infective Agents, Local
Glaucoma
Eye Diseases
Cardiovascular Agents
Healthy
Antihypertensive Agents

Latanoprost
Benzalkonium Compounds
Travoprost
Hypertension
Ocular Hypertension

Additional relevant MeSH terms:

Anti-Infective Agents
Anti-Infective Agents, Local
Glaucoma
Therapeutic Uses
Eye Diseases
Cardiovascular Agents

Antihypertensive Agents
Latanoprost
Pharmacologic Actions
Benzalkonium Compounds
Travoprost
Ocular Hypertension

ClinicalTrials.gov processed this record on May 06, 2009